Loading...

IMUX IMMUNIC INC Other Situations 8-K Filing

MMNC

MX

IMMUNIC INC

(IMUX)

2026 8-K

Trial Data Update

Management Change

New Board Chair

Financial Results Report

Management Changes

Stock Split Approval

Stock Split Approval

CEO Retention Bonus

Nasdaq Compliance Regained

Board Appointment

Financial Results Update

Capital Raising Event

Stock Listing Change

Executive Changes

Financial Results Update

Data Presentation Update

Financial Statements

Notice of Delisting

Rights Offerings

Equity Offerings

Equity Offerings

Clinical Trial Update

CEO Employment Agreement

Financial Results

Positive Trial Results

R&D Day Summary

Management Change

Financial Results Announcement

Appointment of Director

Appointment of COO and Pres...

Annual Meeting of Stockholders

Earnings Reports

Amendment to Increase Autho...

Financial Results and Corpo...

Private Placement

Management Agreements

Financial Results Announcement

Extension of Employment Ter...

Positive Interim Data from ...

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Report

Clinical Trial Results

Appointments, Retirement

Press Release and Presentation

Liquidity Concern at Silico...

Financial Results Announcement

Press Release and Presentation

Management Agreements

External Links:

On May 28, 2026, Immunic, Inc. announced additional findings from its phase 2 CALLIPER trial for IMU-838, focusing on progressive multiple sclerosis, presented at the CMSC Annual Meeting. This filing is significant as it contains new clinical results that could impact investor sentiment.

AI Assistant

IMMUNIC INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.